Journal ArticleDOI
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.
Constance Mao,Laura A. Koutsky,Kevin A. Ault,Cosette M. Wheeler,Darron R. Brown,Dorothy J. Wiley,Frances B. Alvarez,Oliver Bautista,Kathrin U. Jansen,Eliav Barr +9 more
Reads0
Chats0
TLDR
The vaccine HPV16 L1 VLP provides high-level protection against persistent HPV16 infection and HPV16-related CIN2–3 for at least 3.5 years after immunization, likely to reduce risk for cervical cancer.About:
This article is published in Obstetrics & Gynecology.The article was published on 2006-01-01. It has received 480 citations till now. The article focuses on the topics: Vaccine trial & Vaccine efficacy.read more
Citations
More filters
Journal ArticleDOI
Human papillomavirus and cervical cancer
TL;DR: The new HPV-oriented model of cervical carcinogenesis should gradually replace older morphological models based only on cytology and histology, and can minimise the incidence of cervical cancer, and the morbidity and mortality it causes, even in low-resource settings.
Journal ArticleDOI
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
Luisa L. Villa,Gonzalo Perez,Susanne K. Kjaer,Jorma Paavonen,Matti Lehtinen,Nubia Muñoz,Kristjan Sigurdsson,Mauricio Hernández-Ávila,Finn Egil Skjeldestad,Steinar Thoresen,Patricia J. Garcia,Slawomir Majewski,Joakim Dillner,Sven Eric Olsson,Hseon Tay Eng,F. Xavier Bosch,Kevin A. Ault,Darron R. Brown,Daron G. Ferris,Laura A. Koutsky,Robert J. Kurman,Evan R. Myers,Eliav Barr,John W. Boslego,Janine T. Bryan,Mark T. Esser,Christine K. Gause,Teresa M. Hesley,Lisa Lupinacci,Heather L. Sings,Frank J. Taddeo,Annemarie R. Thornton +31 more
TL;DR: In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV- 16 or HPV -18 than did those inThe placebo group.
Journal Article
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Lauri E. Markowitz,Eileen F. Dunne,Mona Saraiya,Herschel W. Lawson,Harrell W. Chesson,Elizabeth R. Unger +5 more
TL;DR: The first statement by the Advisory Committee on Immunization Practices (ACIP) on the use of a quadrivalent human papillomavirus (HPV) vaccine was made by the U.S. Food and Drug Administration on June 8, 2006 as mentioned in this paper.
Journal ArticleDOI
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
Luisa L. Villa,Ronaldo L.R. Costa,Carlos Alberto Petta,Rosires Pereira de Andrade,Jorma Paavonen,O-E Iversen,S-E Olsson,J. Hoye,Margareta Steinwall,G. Riis-Johannessen,A. Andersson-Ellstrom,Kristina Elfgren,G. Von Krogh,Matti Lehtinen,Christian Malm,Gretchen M. Tamms,Katherine E.D. Giacoletti,Lisa Lupinacci,Radha Railkar,Frank J. Taddeo,Janine T. Bryan,Mark T. Esser,Heather L. Sings,Alfred Saah,Eliav Barr +24 more
TL;DR: A prophylactic quadrivalent HPV vaccine was effective through 5 years for prevention of persistent infection and disease caused by HPV 6/11/16/18, and this duration supports vaccination of adolescents and young adults.
References
More filters
Journal ArticleDOI
Natural history of cervicovaginal papillomavirus infection in young women
TL;DR: An increased risk of HPV infection was significantly associated with younger age, Hispanic ethnicity, black race, an increased number of vaginal-sex partners, high frequencies of vaginal sex and alcohol consumption, anal sex, and certain characteristics of partners.
Journal ArticleDOI
A controlled trial of a human papillomavirus type 16 vaccine.
Laura A. Koutsky,Kevin A. Ault,Cosette M. Wheeler,Darron R. Brown,Eliav Barr,Frances B. Alvarez,Lisa M. Chiacchierini,Kathrin U. Jansen +7 more
TL;DR: Administration of this HPV- 16 vaccine reduced the incidence of both HPV-16 infection and HPV-15-related cervical intraepithelial neoplasia, and immunizing HPV-14-negative women may eventually reduce the probability of cervical cancer.
Journal ArticleDOI
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
Diane M. Harper,Eduardo L. Franco,Cosette M. Wheeler,Daron G. Ferris,D. G. Jenkins,Anne Schuind,Toufik Zahaf,Bruce L. Innis,Paulo Naud,Newton Sérgio de Carvalho,Cecilia Roteli-Martins,Julio Cesar Teixeira,Mark M. Blatter,A. Korn,Wim Quint,Gary Dubin +15 more
TL;DR: The bivalent HPV vaccine was efficacious in prevention of incident and persistent cervical infections with HPV-16 and HPV-18, and associated cytological abnormalities and lesions.
Journal ArticleDOI
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
Luisa L. Villa,Ronaldo L.R. Costa,Carlos Alberto Petta,Rosires Pereira de Andrade,Kevin A. Ault,Anna R. Giuliano,Cosette M. Wheeler,Laura A. Koutsky,Christian Malm,Matti Lehtinen,Finn Egil Skjeldestad,Sven Eric Olsson,Margareta Steinwall,Darron R. Brown,Robert J. Kurman,Brigitte M. Ronnett,Mark H. Stoler,Alex Ferenczy,Diane M. Harper,Gretchen M. Tamms,Jimmy Yu,Lisa Lupinacci,Radha Railkar,Frank J. Taddeo,Kathrin U. Jansen,Mark T. Esser,Heather L. Sings,Alfred Saah,Eliav Barr +28 more
TL;DR: In this paper, a double-blind placebo-controlled phase II study was done to assess the efficacy of a prophylactic quadrivalent vaccine targeting the human papillomavirus (HPV) types associated with 70% of cervical cancers (types 16 and 18) and with 90% of genital warts (types 6 and 11).
Journal ArticleDOI
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.
TL;DR: A majority of ICC was associated with HPV16 or 18 in all regions, but approximately a quarter of all ICC cases were associated with one of 16 other HPV types, their distribution varying by region.
Related Papers (5)
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
Luisa L. Villa,Ronaldo L.R. Costa,Carlos Alberto Petta,Rosires Pereira de Andrade,Kevin A. Ault,Anna R. Giuliano,Cosette M. Wheeler,Laura A. Koutsky,Christian Malm,Matti Lehtinen,Finn Egil Skjeldestad,Sven Eric Olsson,Margareta Steinwall,Darron R. Brown,Robert J. Kurman,Brigitte M. Ronnett,Mark H. Stoler,Alex Ferenczy,Diane M. Harper,Gretchen M. Tamms,Jimmy Yu,Lisa Lupinacci,Radha Railkar,Frank J. Taddeo,Kathrin U. Jansen,Mark T. Esser,Heather L. Sings,Alfred Saah,Eliav Barr +28 more
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
Luisa L. Villa,Gonzalo Perez,Susanne K. Kjaer,Jorma Paavonen,Matti Lehtinen,Nubia Muñoz,Kristjan Sigurdsson,Mauricio Hernández-Ávila,Finn Egil Skjeldestad,Steinar Thoresen,Patricia J. Garcia,Slawomir Majewski,Joakim Dillner,Sven Eric Olsson,Hseon Tay Eng,F. Xavier Bosch,Kevin A. Ault,Darron R. Brown,Daron G. Ferris,Laura A. Koutsky,Robert J. Kurman,Evan R. Myers,Eliav Barr,John W. Boslego,Janine T. Bryan,Mark T. Esser,Christine K. Gause,Teresa M. Hesley,Lisa Lupinacci,Heather L. Sings,Frank J. Taddeo,Annemarie R. Thornton +31 more